NAXITAMAB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Wed Apr 02 08:58:31 GMT 2025` Edited by `admin` on `Wed Apr 02 08:58:31 GMT 2025`
Protein Type	MONOCLONAL ANTIBODY
Protein Sub Type	IGG1
Sequence Origin	HUMANIZED MOUSE
Sequence Type	COMPLETE
Record UNII	9K8GNJ2874
Record Status	`Validated (UNII)`
Record Version

Download

Related Record	Type

Name

Type

Language

NAXITAMAB

Official Name

English

HU3F8

Preferred Name

English

HUMANIZED 3F8

Common Name

English

ANTI-GD2 MONOCLONAL ANTIBODY 3F8 HUMANIZED

Common Name

English

NAXITAMAB [USAN]

Common Name

English

HUMANIZED MONOCLONAL ANTIBODY HU3F8-IGG1

Common Name

English

MONOCLONAL ANTIBODY HU3F8

Common Name

English

naxitamab [INN]

Common Name

English

IMMUNOGLOBULIN G1, ANTI-(GANGLIOSIDE GD2) (HUMANIZED MUS MUSCULUS CLONE HU3F8 .GAMMA.1-CHAIN), DISULFIDE WITH HUMANIZED MUS MUSCULUS CLONE HU3F8 LIGHT-CHAIN, DIMER

Systematic Name

English

ANTI-GD2 IGG3 MONOCLONAL ANTIBODY 3F8 HUMANIZED

Common Name

English

Naxitamab [WHO-DD]

Common Name

English

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS BETA-1,4 N-ACETYLGALACTOSAMINYLTRANSFERASE 1 ((N-ACETYLNEURAMINYL)-GALACTOSYLGLUCOSYLCERAMIDE, GM2/GD2 SYNTHASE))HUMANIZED MOUSE MONOCLONAL ANTIBODY.GAMMA.1 HEAVY CHAIN (1-449) (MUS MUSCULUS VH (IGHV2-9*02 (79%

Systematic Name

English

HUMANIZED ANTI-GD2 MONOCLONAL ANTIBODY 3F8

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

416313

Created by admin on Wed Apr 02 08:58:31 GMT 2025 , Edited by admin on Wed Apr 02 08:58:31 GMT 2025

NCI_THESAURUS

C20401

Created by admin on Wed Apr 02 08:58:31 GMT 2025 , Edited by admin on Wed Apr 02 08:58:31 GMT 2025

EU-Orphan Drug

EU/3/18/2094

Created by admin on Wed Apr 02 08:58:31 GMT 2025 , Edited by admin on Wed Apr 02 08:58:31 GMT 2025

FDA ORPHAN DRUG

399613

Created by admin on Wed Apr 02 08:58:31 GMT 2025 , Edited by admin on Wed Apr 02 08:58:31 GMT 2025

Code System Code Type Description

CAS

1879925-92-4

Created by admin on Wed Apr 02 08:58:31 GMT 2025 , Edited by admin on Wed Apr 02 08:58:31 GMT 2025

PRIMARY

INN

10918

Created by admin on Wed Apr 02 08:58:31 GMT 2025 , Edited by admin on Wed Apr 02 08:58:31 GMT 2025

PRIMARY

DAILYMED

9K8GNJ2874

Created by admin on Wed Apr 02 08:58:31 GMT 2025 , Edited by admin on Wed Apr 02 08:58:31 GMT 2025

PRIMARY

EVMPD

SUB192785

Created by admin on Wed Apr 02 08:58:31 GMT 2025 , Edited by admin on Wed Apr 02 08:58:31 GMT 2025

PRIMARY

RXCUI

2474039

Created by admin on Wed Apr 02 08:58:31 GMT 2025 , Edited by admin on Wed Apr 02 08:58:31 GMT 2025

PRIMARY

NCI_THESAURUS

C123428

Created by admin on Wed Apr 02 08:58:31 GMT 2025 , Edited by admin on Wed Apr 02 08:58:31 GMT 2025

PRIMARY

SMS_ID

100000177409

Created by admin on Wed Apr 02 08:58:31 GMT 2025 , Edited by admin on Wed Apr 02 08:58:31 GMT 2025

PRIMARY

FDA UNII

9K8GNJ2874

Created by admin on Wed Apr 02 08:58:31 GMT 2025 , Edited by admin on Wed Apr 02 08:58:31 GMT 2025

PRIMARY

From	To
1_231	2_231
1_228	2_228
2_222	4_211
1_222	3_211
4_131	4_191
4_23	4_88
3_131	3_191
3_23	3_88
2_369	2_427
2_263	2_323
2_146	2_202
2_22	2_95
1_369	1_427
1_263	1_323
1_146	1_202
1_22	1_95

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_299
N	2_299

Related Record Type Details

SUB_CONCEPT->SUBSTANCE

Amount:


					53HAP569KS

NAXITAMAB I-124

LABELED -> NON-LABELED

Related Record Type Details


					9K8GNJ2874

NAXITAMAB

ACTIVE MOIETY

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO ACID REMOVAL	[1_449] [2_449]	C-TERMINUS			LYSINE	K3Z4F929H6
AMINO ACID SUBSTITUTION	[1_1] [2_1]				PIDOLIC ACID	SZB83O1W42

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
MOL_WEIGHT:ESTIMATED	CHEMICAL